SC
ONCY

Sophrosyne Capital’s ONCOLYTICS BIOTECH INC ONCY Stock Holding History

Sophrosyne Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-222,900
Closed -$345K – 94
2013
Q4 		$345K Buy
+222,900
New +$502K 0.3% 42

Other funds holding ONCY

1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
RFC
Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
AII
AGF Investments Inc Toronto, Ontario, Canada $10.6B AUM 4.37% 1-Year Est. Return
VFS
VSR Financial Services Overland Park, Kansas $607M AUM 0.85% 1-Year Est. Return
Canada Life
Canada Life Winnipeg, Manitoba, Canada $62.7B AUM 37.65% 1-Year Est. Return

Sophrosyne Capital's ONCY Position: Q1 2014 in Review

Sophrosyne Capital sold out of ONCOLYTICS BIOTECH INC (ONCY) in Q1 2014, closing a stake of 222,900 shares — an estimated $345K sold.

Sophrosyne Capital first reported a position in ONCY in Q4 2013 and held it in 1 quarter. The position peaked at $345K in Q4 2013. 34 funds tracked by Wall St. Rank hold ONCY as of Q1 2014.

  • Sophrosyne Capital reported no remaining ONCOLYTICS BIOTECH INC position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 222,900 ONCOLYTICS BIOTECH INC shares in Q1 2014, an estimated $345K.
  • Sophrosyne Capital first reported a position in ONCOLYTICS BIOTECH INC in Q4 2013 and held it in 1 quarter.
  • Sophrosyne Capital's ONCOLYTICS BIOTECH INC position peaked at $345K in Q4 2013.
  • 34 funds tracked by Wall St. Rank held ONCOLYTICS BIOTECH INC as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.